The Mayo Clinic's Office of Intellectual Property has signed a three-year research deal with Milan, Italy-based Sorin Group to work on a less invasive aortic heart-valve implant. The OVATIO ™ will be distributed in the United States by ELA Medical Inc, a Sorin Group Company.

The collapsible heart valve will be implanted through a small incision in the apex of the heart and will be minimally invasive --not requiring a heart lung machine.

The agreement will use the Sorin Group's new sutureless collapsible heart valve which has already been successfully implanted in humans. Leveraging on its extensive cardiac experience, Sorin and Mayo, will develop the therapy and the ancillary instruments needed for the successful execution of the implant and delivery of the valve. Once the implantation procedure is ready, Mayo will participate in U.S. clinical trials.

The OVATIO™ CRT will be distributed in the United States by ELA Medical, Inc., a Sorin Group Company.

About the Sorin Group
The Sorin Group is a world leader in the development of medical technologies for cardiac surgery, offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases. The Sorin Group brands include: Dideco, CarboMedics, COBE Cardiovascular, Stöckert, Mitroflow, ELA Medical, Sorin Biomedica, Bellco and Bellco- Soludia. At the Sorin Group 4,500 employees work to serve over 5,000 public and private treatment centers in more than 80 countries throughout the world.

For more information, visit: www.sorin.com or www.sorin-crm.com.

More Voices